Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Natera announced that its Signatera test received regulatory approval from Japan’s PMDA for colorectal cancer in the adjuvant setting, marking the first MRD test approved in the country. Commercial launch is anticipated by the end of 2026, pending final pricing and reimbursement decisions, backed by position statements from major Japanese oncology societies.
Key figures
- Galaxy samples analyzed
- 2240
- Crc incidence japan annual
- 150000
- Circulate japan institutions
- >150
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.